Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases - PubMed
3 hours ago
- #KRAS G12C
- #brain metastases
- #NSCLC
- JMKX1899 is a blood-brain barrier-penetrating KRAS G12C inhibitor studied for NSCLC with brain metastases.
- Preclinical studies show JMKX1899 selectively inhibits KRAS G12C-mutant cells with potency comparable or superior to AMG510 and MRTX849.
- The inhibitor demonstrates significant cerebrospinal fluid penetration, leading to tumor regression and improved survival in brain metastasis models.
- Early clinical data in KRAS G12C-mutant NSCLC patients with brain metastases confirm its BBB penetration and antitumor activity.
- These findings support further clinical development of JMKX1899 as a therapeutic option for this patient population.